lundi 24 août 2015

Onco Actu du 24 août 2015 (2/3)

5. Traitements

First trial targeting mutation, not cancer type, gives mixed results [Reuters]

Shorter course of radiation therapy associated with less toxicity, improved quality of life in women with early stage breast cancer [MD Anderson Cancer Center]

Recurrent ovarian cancer patients may have hope [Harvard Gazette]

5.10 Traitements - Essais

Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer [Roche]

Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint [AbbVie]

5.12 Immunothérapies

Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief [Forbes]

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration [Sanofi]

Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical ollaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. [BMS]

Sanofi Pays to Get Back Into Oncology [In the Pipeline]

Sanofi, Regeneron Set Sights on Immuno-Oncology With New $2B+ Pact [Xconomy]

Immuno-oncology deal frenzy continues as Merck partners with MD Anderson [FierceBiotech]

Merck and MD Anderson announce immuno-oncology research collaboration in solid tumors [MD Anderson Cancer Center]

AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments [AstraZeneca]

Pfizer, Bristol revive cancer drugs that rev up immune system [Reuters]

5.2 Pharma

Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer [FierceBiotech]

Juno Announces FDA Clearance of Investigational New Drug Application for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia [Juno]

5.2.1 Pharma - Partenariats

MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer [AstraZeneca]

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer [Boehringer Ingelheim]

5.2.2 Pharma - Fusions & Acquisitions

Merck Strengthens Immuno-oncology Pipeline with cCAM Biotherapeutics Acquisition [GEN]

5.2.3 Pharma - économie

With $16M Series B, Antiva Hopes to Kill Cancer-Causing HPV [Xconomy]

New analysis underscores improving pharma R&D productivity [Reuters]

Study: Firms “underinvest” in long-term cancer research [MIT News]

5.3 Traitements - FDA, EMA,...

Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients [Novartis]

Roche's Perjeta regimen approved in Europe for use before surgery in early stage aggressive breast cancer [Roche]

Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer | Pfizer Pharmaceutical News and Media [Pfizer]

Does the FDA Reject Anything Any More? [In the Pipeline]

The FDA Is Basically Approving Everything. Here's The Data To Prove It [Forbes]

Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones [Novartis]

AstraZeneca Exec Discusses Iressa's Future in the U.S. [The Cancer Letter]

FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase [BMS]

European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) For the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies [BMS]

U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma [BMS]

CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer [Boehringer Ingelheim]

Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation [Seattle Genetics]

European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma [Takeda]

5.3.4 Traitements - AMM (FDA, EMA)

The Times They Are a Changin’ – And So is FDA [FDA Voice]

Fast track routes for medicines that address unmet medical needs [EMA]

FDA approves new treatment for most common form of advanced skin cancer [FDA]

5.4 Traitements - Economie

NHS cancer drug approval needs radical change [The Telegraph]

NICE developing new guidance to care for people with incurable blood cancer [NICE]

New cocktails to test limits of cancer drug pricing [Reuters]

NICE asks company for more information on olaparib for ovarian, fallopian tube and peritoneal cancer [NICE]

Bowel cancer patients will be 'thrown into dark ages' if drugs denied [TheTelegraph]

The War on Cancer (Drug Prices): Political Education of Hagop Kantarjian [The Cancer Letter]

If we don’t talk about value, cancer drugs will become terminal for health systems [The Conversation]